Literature DB >> 750104

In vivo toxicity to lymphoid tissue by 2'-deoxycoformycin.

J F Smyth, R C Young, D M Young.   

Abstract

The enzyme adenosine deaminase has an essential role in lymphocyte metabolism. To examine the in vivo effects of inhibition of this enzyme healthy BDF1 mice were injected intraperitoneally with 2'-deoxycoformycin, a stoichiometric tight-binding inhibitor of adenosine deaminase. Of the treated animals, 20% died of overwhelming infection, and histopathological examination of these, and surviving animals sacrificed 10 days following treatment indicated a selective toxicity to lymphoid cells. No toxicity to tissues other than the lymphoid system was observed, which is consistent with the hypothesis that 2'-deoxycoformycin offers a new and selective approach to the treatment of lymphoid malignancies.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 750104     DOI: 10.1007/bf00253146

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Enhancement of the biological activity of cordycepin (3'-deoxyadenosine) by the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  D G Johns; R H Adamson
Journal:  Biochem Pharmacol       Date:  1976-06-15       Impact factor: 5.858

2.  A STUDY OF THE TISSUE DISTRIBUTION OF ADENOSINE DEAMINASE IN SIX MAMMAL SPECIES.

Authors:  T G BRADY; C I O'DONOVAN
Journal:  Comp Biochem Physiol       Date:  1965-01

3.  Adenosine deaminase activity in lymphoid cells during antibody production.

Authors:  J G HALL
Journal:  Aust J Exp Biol Med Sci       Date:  1963-02

4.  The deaminases of adenosine and adenylic acid in blood and tissues.

Authors:  E J Conway; R Cooke
Journal:  Biochem J       Date:  1939-04       Impact factor: 3.857

5.  Adenosine deaminase.

Authors:  T Brady
Journal:  Biochem J       Date:  1942-06       Impact factor: 3.857

6.  Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin.

Authors:  G A LePage; L S Worth; A P Kimball
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

7.  Adenosine-deaminase deficiency and combined immunodeficiency syndrome.

Authors:  J Dissing; B Knudsen
Journal:  Lancet       Date:  1972-12-16       Impact factor: 79.321

8.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

9.  Role of adenosine deaminase in lymphocyte proliferation.

Authors:  T Hovi; J F Smyth; A C Allison; S C Williams
Journal:  Clin Exp Immunol       Date:  1976-03       Impact factor: 4.330

10.  Adenosine deaminase activity in leukaemia.

Authors:  J F Smyth; K R Harrap
Journal:  Br J Cancer       Date:  1975-05       Impact factor: 7.640

  10 in total
  12 in total

1.  Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

Authors:  J F Smyth; D G Poplack; B J Holiman; B G Leventhal; G Yarbro
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

2.  Physiologic model for the pharmacokinetics of 2'deoxycoformycin in normal and leukemic mice.

Authors:  F G King; R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

3.  Acute respiratory failure due to 2'Deoxycoformycin.

Authors:  R C Kahn; G C Carlon; L Miller; W S Howland; C Tan
Journal:  Intensive Care Med       Date:  1982-03       Impact factor: 17.440

Review 4.  Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression.

Authors:  R I Glazer
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 5.  Biochemical enzyme analysis in acute leukaemia.

Authors:  H G Drexler; G Gaedicke; J Minowada
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

6.  Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations.

Authors:  H Ratech; M A Greco; G Gallo; D L Rimoin; H Kamino; R Hirschhorn
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

7.  Deoxycoformycin toxicity in mice after long-term treatment.

Authors:  R P Agarwal
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  J F Smyth; R M Paine; A L Jackman; K R Harrap; M M Chassin; R H Adamson; D G Johns
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Action of deoxycoformycin on human T cell colonies in vitro.

Authors:  N R Colledge; A S Krajewski; J F Smyth; A H Wyllie
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

10.  Adenosine and deoxyadenosine toxicity in colony assay systems for human T-lymphocytes, B-lymphocytes, and granulocytes.

Authors:  L W Brox; E Pollock; A Belch
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.